Disease assessment
PD
REMISSION, DISEASE, DISEASE

Disease response and treatment duration in each patient, with baseline characteristics. Commercial drugs: patients received commercially available venetoclax + LDAC after approval of venetoclax in Japan. venetoclax treatment, open treatment period; CR, complete remission; CRi, CR with incomplete blood count recovery; MLFS, morphologic leukemia-free state; RD, resistant disease; PD, progressive disease.Bone marrow blast count change after the initial administration of venetoclax. Bone marrow aspiration or biopsy for disease assessment was conducted at screening and was done at the investigator’s discretion according to patients’ physical findings or peripheral blood results.